Simmons Bank Gilead Sciences, Inc. Transaction History

Simmons Bank

$1.37 Billion
Q3 2024

A detailed history of Simmons Bank transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Simmons Bank holds 39,664 shares of GILD stock, worth $3.73 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares

39,664

Previous 43,030 7.82%

Holding current value

$3.73 Million

Previous $2.95 Million 12.6%

% of portfolio

0.24%

Previous 0.23%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	SELL	$66.59 - $83.99 $224,141 - $282,710	-3,366 Reduced 7.82%	39,664 $3.32 Million
Q2 2024 Jul 26, 2024	BUY	$63.15 - $72.88 $29,301 - $33,816	464 Added 1.09%	43,030 $2.95 Million
Q1 2024 May 14, 2024	SELL	$71.58 - $87.29 $316,240 - $385,647	-4,418 Reduced 9.4%	42,566 $3.12 Million
Q4 2023 Feb 06, 2024	SELL	$73.27 - $83.09 $44,767 - $50,767	-611 Reduced 1.28%	46,984 $3.81 Million
Q3 2023 Oct 26, 2023	BUY	$73.94 - $80.67 $49,391 - $53,887	668 Added 1.42%	47,595 $3.57 Million
Q2 2023 Aug 03, 2023	BUY	$76.01 - $86.7 $34,052 - $38,841	448 Added 0.96%	46,927 $3.62 Million
Q1 2023 Apr 28, 2023	BUY	$77.31 - $88.08 $28,218 - $32,149	365 Added 0.79%	46,479 $3.86 Million
Q4 2022 Feb 08, 2023	SELL	$62.32 - $89.47 $1,807 - $2,594	-29 Reduced 0.06%	46,114 $3.96 Million
Q3 2022 Oct 27, 2022	BUY	$59.54 - $68.01 $63,707 - $72,770	1,070 Added 2.37%	46,143 $2.85 Million
Q2 2022 Jul 29, 2022	BUY	$57.72 - $65.01 $179,566 - $202,246	3,111 Added 7.41%	45,073 $2.79 Million
Q1 2022 Apr 21, 2022	BUY	$57.92 - $72.58 $9,614 - $12,048	166 Added 0.4%	41,962 $2.49 Million
Q4 2021 Jan 28, 2022	SELL	$64.88 - $73.64 $127,164 - $144,334	-1,960 Reduced 4.48%	41,796 $3.04 Million
Q3 2021 Oct 26, 2021	BUY	$67.69 - $73.03 $23,149 - $24,976	342 Added 0.79%	43,756 $3.06 Million
Q2 2021 Aug 05, 2021	SELL	$63.47 - $69.35 $102,757 - $112,277	-1,619 Reduced 3.6%	43,414 $2.99 Million
Q1 2021 May 06, 2021	SELL	$60.0 - $68.46 $55,800 - $63,667	-930 Reduced 2.02%	45,033 $2.91 Million
Q4 2020 Feb 08, 2021	BUY	$56.65 - $64.55 $44,810 - $51,059	791 Added 1.75%	45,963 $2.68 Million
Q3 2020 Nov 13, 2020	SELL	$62.1 - $78.08 $715,205 - $899,247	-11,517 Reduced 20.32%	45,172 $2.86 Million
Q2 2020 Aug 14, 2020	BUY	$72.34 - $84.0 $166,092 - $192,864	2,296 Added 4.22%	56,689 $4.36 Million
Q1 2020 May 14, 2020	BUY	$62.63 - $80.22 $2.38 Million - $3.05 Million	38,068 Added 233.19%	54,393 $4.07 Million
Q4 2019 Jan 31, 2020	SELL	$61.62 - $67.78 $168,838 - $185,717	-2,740 Reduced 14.37%	16,325 $1.06 Million
Q3 2019 Nov 13, 2019	SELL	$62.51 - $69.0 $49,132 - $54,234	-786 Reduced 3.96%	19,065 $1.21 Million
Q2 2019 Aug 13, 2019	SELL	$61.87 - $69.38 $10,827 - $12,141	-175 Reduced 0.87%	19,851 $1.34 Million
Q1 2019 May 13, 2019	SELL	$62.53 - $70.05 $13,756 - $15,411	-220 Reduced 1.09%	20,026 $1.3 Million
Q4 2018 Jan 24, 2019	BUY	$60.54 - $79.0 $38,382 - $50,086	634 Added 3.23%	20,246 $1.27 Million
Q3 2018 Nov 13, 2018	SELL	$71.28 - $78.92 $175,990 - $194,853	-2,469 Reduced 11.18%	19,612 $1.51 Million
Q2 2018 Aug 13, 2018	SELL	$64.88 - $75.68 $72,665 - $84,761	-1,120 Reduced 4.83%	22,081 $1.57 Million
Q1 2018 May 14, 2018	BUY	$72.84 - $88.8 $17,554 - $21,400	241 Added 1.05%	23,201 $1.75 Million
Q4 2017 Feb 13, 2018	SELL	$71.15 - $83.52 $142,869 - $167,708	-2,008 Reduced 8.04%	22,960 $1.65 Million
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $143,066 - $169,572	1,984 Added 8.63%	24,968 $2.02 Million
Q2 2017 Aug 15, 2017	BUY	N/A	22,984	22,984 $1.63 Million

Others Institutions Holding GILD

# of Institutions

1,926

Shares Held

992M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $118B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Simmons Bank, based on Form 13F filings with the SEC.

News

Stay updated on Simmons Bank with notifications on news.

Account